FEATURED ARTICLES

• The Bioanalysis CRO Selection Checklist Every Sponsor Should Use Before Signing An MSA

  Choosing a CRO requires more than proposals. Assess reliability, automation, GLP rigor, scientific engagement, pricing clarity, and capacity to find partners who deliver defensible data on real timelines.

• GLP Compliance In A Modern Lab: What Compliant Actually Requires In 2025

  GLP compliance isn’t binary. Real defensibility depends on rigorous QA, validated electronic systems, and operational maturity — not just a label.

• Why ddPCR Is Becoming The Standard For Gene Therapy Biodistribution

  ddPCR is becoming essential for biodistribution because it delivers precise, low‑copy quantification qPCR can’t reliably match. Sponsors need partners with true ddPCR depth to ensure consistent, defensible data across tissues and studies.

• What Sponsors Get Wrong When Selecting A CRO

  Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

• Why CGT Programs Need A Different CRO Mindset

  Advanced therapies need bioanalysis partners built for complexity, not scale. CGT expertise, specialized platforms, and flexible timelines ensure dosing and safety data traditional CROs can’t support.

• Transparent Pricing In Bioanalysis: A Feature, Not A Bonus

  Unclear CRO pricing leaves small biotechs vulnerable to budget swings. Transparent, itemized costs cut financial risk, sharpen planning, and build trust by setting expectations from the start.

• How Smaller Biotechs Are Rethinking CRO Relationships Post-Pandemic

  Smaller biotechs are rethinking CRO partnerships, valuing speed, scientific access, flexibility, and transparent pricing over scale — driven by pandemic lessons and a sharper focus on operational fit.

• The Bioanalysis Report You Actually Get Back Fast

  Manual bioanalysis variability creates data noise. Automation replaces inconsistencies with repeatable processes that boost precision, support compliance, and deliver more reliable results.

• Reducing Human Variability in Bioanalysis

  Automation removes manual variability, creating consistent, repeatable processes that improve precision, strengthen compliance, and produce more reliable data for critical decisions.

• Why Your Bioanalysis Bottleneck Is Costing You More Than You Think

  This piece explains why turnaround time is a strategic variable, where speed is truly achievable, and how automation reshapes the path from sample submission to decision‑ready data.

• How A Strategic Bioanalysis CRO Partnership Empowers Sponsors

  Choosing the right bioanalysis CRO is vital to avoid costly delays. Sponsors need evaluation strategies that prioritize proven quality, predictable timelines, and submission-ready data.

• 5 Questions That Put Sponsors Back in Control of Bioanalysis Projects

  Bioanalysis service quality significantly impacts project success. Don't settle for typical CRO claims; demand better technology, pricing transparency, and dedicated partnership.

• Building Bioanalysis Infrastructure For Modern Drug Development

  Drug development accelerates with AI, decentralized trials, and adaptive protocols, but legacy CRO infrastructure lags. Platform-based systems enable speed, quality, automation, and continuous improvement.

• 5 Outdated Practices Holding Back Modern Bioanalysis

  Bioanalysis must replace outdated paper, manual processes, and disjointed systems with integrated, automated platforms for continuous validation, efficiency, compliance, and to support complex modern therapies.

• Built Like A Tech Company: Why CROs Need A New Operating System

  See why building digital, automated infrastructure is essential, and better aligns CROs with today's speed, compliance, and innovation needs.

• Five Questions Biotechs Should Ask Before Selecting A Bioanalytical CRO

  In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional; it is essential to survival and success.

• Accelerating IND-Enabling Studies With Automated Bioanalysis Workflows

  Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.

• Why Bioanalysis Needs To Break Free From Manual Bottlenecks

  Bioanalysis remains one of the most persistent bottlenecks in drug development, with CROs displaying inefficiencies that are no longer operational nuisances but strategic liabilities.